Founded in 2007 and headquartered in San Diego, California, Organovo Holdings, Inc. is a pioneering biotech company specializing in 3D bioprinting technology. The company's core mission is to create functional, three-dimensional human tissues for medical research and therapeutic applications. Organovo's innovative bioprinting solutions are designed to enhance drug discovery processes and offer potential advancements in regenerative medicine. Serving a global market, the company aims to revolutionize the way researchers and clinicians approach tissue engineering and disease modeling.

Notable figures associated with Organovo include Taylor J. Crouch, who has served as CEO. The company is publicly traded on Nasdaq under the ticker symbol ONVO and is a component of the Russell 2000 Index. Organovo has achieved significant milestones, including presenting groundbreaking data at major medical conferences such as Digestive Disease Week. With total assets of over $62 million as of 2016 and a revenue of $4.23 million in 2017, Organovo continues to make a substantial impact in the biotech industry by advancing the capabilities of 3D bioprinting technology.